Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 1, 2010, Pages 34-38

  Tombolini, V ^a   Di Staso, M ^b   Bonfili, P ^b   Di Genesio Pagliuca, M ^a   Franzese, P ^d   Buonopane, S ^b   Valeriani, M ^d   Maurizi Enrici, R ^d   Festuccia, C ^c   Gravina, G L ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAN SALVATORE HOSPITAL   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Hormonal therapy; Hypofractionated radiotherapy; IPSS; Urinary morbidity; Uroflowmetry

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BICALUTAMIDE; LEUPRORELIN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; DOSIMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; SYMPTOM; TREATMENT RESPONSE; URINE FLOW RATE; UROGENITAL TRACT DISEASE;

AGED; ANILIDES; COMBINED MODALITY THERAPY; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NITRILES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; TOSYL COMPOUNDS; TREATMENT OUTCOME; URINATION DISORDERS; UROGENITAL SYSTEM;

EID: 76949092679     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.23     Document Type: Article

References (21)

1. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097-1105.
2. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491-500.
3. Brenner DJ. Towards optimal external beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys 2000; 48: 315-316.
4. Brenner DJ, Hall EJ. Fractionation protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095-1101.
5. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001; 50: 1021-1031.
6. Wang JZ, Guerrero M, Li XA. How low is the alpha/beta ratio for the prostate cancer? Int J Radiat Oncol Biol Phys 2003; 55: 194-203.
7. Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: what is it, really? Radiother Oncol. 2005; 76: 1-3.
8. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long term outcomes. Int J Radiat Oncol Biol Phys 2005; 63: 1463-1468.
9. Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J et al. Phase II trial of hypofractionated image-guided intensitymodulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys; 2007; 69: 1084-1089.
10. Soete G, Arcangeli S, De Meerleer G, Landoni V, Fonteyne V, Arcangeli G, De NeveW, Storme G et al. Phase II study of a fourweek hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol; 2006; 80: 78-81.
11. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L et al. Quality of life and satisfaction with outcome among prostate-cancer survivor. N Engl J Med 2008; 358: 1250-1261.
12. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2005; 292: 821-827.
13. Michalski JM, Purdy JA, Winter K, Roach III M, Vijayakumar S, Sandler HM et al. Preliminary reports of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Biol Phys 2000; 46: 391-402.
14. Diaz A, Roach M, Marquez C, Coleman L, Pickett B, Wolfe JS et al. Indications for and the significance of seminal vesicles irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 30: 323-329.
15. Coia LR, Minsky BD, John M. Decision trees and management guidelines. Semin Radiat Oncol 1997; 7: 163-181.
16. Gravina GL, Costa AM, Ronchi P, Galatioto GP, Luana G, Vicentini C. et al. Bladder outlet obstruction index and maximal flow rate during urodynamic study as powerful predictors for the detection of urodynamic obstruction in women. Neurourol Urodyn 2007; 26: 247-253.
17. Ronchi P, Gravina GL, Galatioto GP, Costa AM, Martella O, Vicentini C et al. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. Neurourol Urodyn 2009; 28: 52-57.
18. Sand PK, Dmochowski R. Analysis of the standardization of terminology of lower urinary tract dysfunction: report from the Standardisation Sub-Committee of the International Incontinence Society. Neurourol Urodyn 2002; 21: 167.
19. Johnstone PAS, Gray C, Powel CR. Quality of life in T 1-3N0 prostate cancer patients with radiation therapy with minimum 10-year follow-up. Int J Radiat Oncol Biol Phys 2000; 46: 833-838.
20. Brenner DJ. Fractionation late rectal toxicity. Int J Radiat Oncol Biol Phys 2004; 60: 1013-1015.
21. Beekman M, Merrick GS, Butler WM, Allner KE, Allen ZA, Galbreath RW et al. Selecting patients with pre-treatment postvoid residual urine volume less than 100 ml may favourably influence brachytherapy-related urinary morbidity. Urology 2005; 66: 1266-1270.